<DOC>
	<DOCNO>NCT02321501</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose ceritinib ( LDK378 ) everolimus give patient NSCLC head neck cancer . The safety drug combination also test .</brief_summary>
	<brief_title>Phase I/Ib Dose Escalation &amp; Biomarker Study Ceritinib ( LDK378 ) + Everolimus Locally Advanced Metastatic Solid Tumors With Expansion Non-Small Cell Lung Cancer ( NSCLC ) Characterized Abnormalities Anaplastic Lymphoma Kinase ( ALK ) Expression</brief_title>
	<detailed_description>Study Groups Study Drug Administration : If find eligible part study , dose LDK378 receive depend join study . The first group participant receive low dose level LDK 378 everolimus . Each new group receive either high dose LDK 378 high dose everolimus group , intolerable side effect see . This continue high tolerable dose LDK 378 everolimus find . Once high tolerable dose find , 30 participant receive drug dose level . You take 2 4 capsule ( depend dose ) LDK 378 mouth 1 time day 28-day study cycle . LDK 378 take morning right ( within 30 minute ) low-fat meal ( 1.5 9 gram fat [ 15 gram ] 100 330 total calorie [ 500 total calorie ] ) . You swallow capsule whole cup water ( 8 ounce ) short time possible ( slow 1 capsule every 2 minute ) . Do chew open capsule . If vomit miss dose , take another dose make . That day 's dose skip , take next dose follow day . You take 1 2 capsule everolimus ( depend dose ) tablets mouth 1 time day 28-day cycle . Everolimus take time every day glass water , either consistently without food Study Visits : On Day 1 Cycle 1 : - You physical exam , include check blood oxygen level . - Blood ( 2 teaspoon ) draw routine test check cholesterol level . You must fast least 12 hour draw . - Blood ( 2 teaspoon draw ) draw pharmacokinetic ( PK ) biomarker test dose LDK378 6 time next 24 hour dose . PK test measure amount study drug body different time point . On Days 8 , 15 , 21 Cycle 1 : - You physical exam . - Blood ( 2 teaspoon ) draw routine test check cholesterol level . You must fast least 12 hour draw . - On Days 15 21 , blood ( 2 teaspoon ) draw PK biomarker test . On Day 1 Cycle 2 : - You physical exam , include check blood oxygen level . - Blood ( 2 teaspoon ) draw routine test check cholesterol level . You must fast least 12 hour draw . - You EKG take study drug . - Blood ( 2 teaspoon draw ) drawn PK test 6 time 1-24 hour dose study drug . - If become pregnant , blood ( ½ teaspoon ) urine collect pregnancy test . On Day 1 Cycle 3 : - You physical exam , include check blood oxygen level . - Blood ( 2 teaspoon ) draw routine test check cholesterol level . You must fast least 12 hour draw . - You EKG take study drug . - Blood ( 2 teaspoon ) draw PK biomarker test . - If become pregnant , blood ( ½ teaspoon ) urine collect pregnancy test . On Day 1 Cycles 3 every cycle ( Cycles 5 , 7 ) , CT scan MRI chest , abdomen , brain check status disease . On Day 1 Cycles 4 beyond : - You physical exam , include check blood oxygen level . - Blood ( 2 teaspoon ) draw routine test check cholesterol level . You must fast least 12 hour draw . - You EKG take study drug . - If become pregnant , blood ( ½ teaspoon ) urine collect pregnancy test . If time disease appear get bad study , FNA core biopsy biomarker test . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study end-of-study visit . End-of-Study Visit : Within 28 day last dose study drug : - You physical exam , include check blood oxygen level . - Blood ( 2 teaspoon ) draw routine test check cholesterol level . You must fast least 12 hour draw . - Blood ( 2 teaspoon ) draw PD test . - If become pregnant , blood ( ½ teaspoon ) urine collect pregnancy test . This investigational study . LDK 378 FDA approve commercially available treatment patient anaplastic lymphoma kinase ( ALK ) -positive metastatic lung cancer ( NSCLC ) progress intolerant crizotinib . Everolimus also FDA approve commercially available treatment advance hormone receptor-positive , HER2-negative breast cancer , advance neuroendocrine tumor pancreatic origin ( PNET ) , advance renal cell carcinoma ( RCC ) , renal angiomyolipoma tuberous sclerosis complex ( TSC ) , subependymal giant cell astrocytoma ( SEGA ) Tuberous Sclerosis Complex ( TSC ) . The combination drug use research purpose . Up 66 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . For dose escalation cohort : Patients histologically cytologically confirm locally advanced metastatic solid tumor fail least one line therapy . 2 . For dose expansion cohort : Patients Stage IIIB IV ALK + NSCLC fail least one line therapy progress ALK inhibitor . 3 . Patient must adequate organ function determine follow laboratory value : Absolute Neutrophil Count ( ANC ) &gt; /= 1,500/microliter ; Platelets &gt; /= 100,000/microliter ; Hemoglobin ( Hgb ) &gt; /= 9 g/dL ; Creatinine &lt; /= 1.5 X upper limit normal ( ULN ) ; Prothrombin Time ( PT ) , Partial Thromboplastin Time ( PTT ) &lt; /= 1.5 X ULN ; Total bilirubin &lt; /= 1.5X ULN ; Alanine Transaminase ( ALT ) Aspartate Aminotransferase ( AST ) &lt; 1.5 X ULN ( &lt; 5 X ULN patient liver metastasis ) 4 . Patient tumor suitable fine needle aspirate ( FNA ) core biopsy research purpose ( 2 FNAs core feasible ) 5 . 18 year age old 6 . Able swallow oral medication 7 . Patient must performance status &lt; /=2 Eastern Cooperative Oncology ( ECOG ) Performance Scale . 8 . Measurable disease RECIST evaluable disease ( e.g. , bone metastasis , lesion fulfill RECIST criterion metastatic disease ) . 9 . ALKpositive NSCLC patient asymptomatic central nervous system ( CNS ) metastases neurologically stable require increase dos steroid within 2 week prior study entry manage CNS symptom . 10 . NonALKpositive NSCLC patient CNS metastasis complete course therapy would eligible study provide clinically stable 1 month prior entry define : ( 1 ) evidence new enlarge CNS metastasis ( 2 ) steroid . 11 . Negative serum urine pregnancy test betaHuman Chorionic Gonadotropin ( beta hCG ) within 2 week prior receive first dose study medication woman childbearing age . 12 . Patient must complete systemic therapy regimen ( except ALK inhibitor ) therapeutic radiation minimum 21 day prior initiation study therapy . 13 . Fasting serum cholesterol &lt; /= 300 mg/dL OR &lt; /= 7.75 mmol/L AND fast triglyceride &lt; /= 2.5x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lowering medication ; 14 . Signed informed consent obtain prior screen procedure . 1 . Patients receive prior everolimus ceritinib 2 . Patients known history extensive disseminate bilateral interstitial fibrosis interstitial lung disease , include history pneumonitis , hypersensitivity pneumonitis , interstitial pneumonia , obliterative bronchiolitis , clinically significant radiation pneumonitis ( i.e . affect activity daily live require therapeutic intervention ) . 3 . Patients currently receive anticancer therapy receive anticancer therapy within 4 week include chemotherapy , radiation therapy , antibody base therapy , etc . ; 4 . Known intolerance hypersensitivity everolimus rapamycin analog ( e.g . sirolimus , temsirolimus ) ; 5 . Patients know hypersensitivity excipients ceritinib ( microcrystalline cellulose , mannitol , crospovidone , colloidal silicon dioxide magnesium stearate ) ; 6 . Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral everolimus ; 7 . Uncontrolled diabetes mellitus define hemoglobin A1c ( HbA1c ) &gt; 8 % despite adequate therapy . Patients known history impair fast glucose diabetes mellitus ( DM ) may include , however blood glucose antidiabetic treatment must monitor closely throughout trial adjust necessary ; 8 . Patient clinically significant , uncontrolled heart disease and/or recent cardiac event ( within 6 month ) , : a. unstable angina within 6 month prior screen ; b. myocardial infarction within 6 month prior screen ; c. history document congestive heart failure ( New York Heart Association functional classification IIIIV ) ; d. uncontrolled hypertension define Systolic Blood Pressure ( SBP ) &gt; /= 160 mm Hg and/or Diastolic Blood Pressure ( DBP ) &gt; /= 100 mm Hg , without antihypertensive medication initiation adjustment antihypertensive medication ( ) allow prior screening ; e. ventricular arrhythmia ; supraventricular nodal arrhythmia control medication ; f. cardiac arrhythmia control medication ; g. correct correct QT interval ( QTc ) &gt; 450 msec use Frederica correction screen electrocardiogram ( ECG ) 9 . Patients severe and/or uncontrolled medical condition : a. active ( acute chronic ) uncontrolled severe infection , liver disease cirrhosis , decompensated liver disease , chronic hepatitis ( i.e . quantifiable hepatitis B virus test [ hepatitis B virus ( HBV ) DNA ] and/or positive hepatitis B surface antigen [ HbsAg ] , quantifiable hepatitis C virus test [ hepatitis C virus ( HCV ) RNA ] ) , b. know severely impaired lung function ( spirometry carbon monoxide diffuse capacity [ DLCO ] 50 % less normal oxygen [ O2 ] saturation 88 % less rest room air ) , c. active , bleeding diathesis ; 10 . Chronic treatment high dose corticosteroid immunosuppressive agent . Topical , inhale , low dose oral corticosteroid allow provide stable dose least 2 week ; 11 . Receiving medication meet one follow criterion discontinue least 1 week prior start treatment ceritinib duration study participation : . Medication know risk prolong QT interval induce Torsades de Pointes b . Strong inhibitor strong inducer CYP3A4/5 c. Medications low therapeutic index primarily metabolize CYP3A4/5 , CYP2C8 and/or CYP2C9 d. Therapeutic dose warfarin sodium ( Coumadin ) coumadinderived anticoagulant . Anticoagulants derive warfarin allow ( eg , dabigatran , rivaroxaban , apixaban ) . e. Unstable increase dos corticosteroid f. enzymeinducing anticonvulsive agent g. herbal supplement 12 . Known history HIV seropositivity ; 13 . Patients receive live attenuate vaccine within 1 week start everolimus study . Patient also avoid close contact others receive live attenuate vaccine . Examples live attenuate vaccine include intranasal influenza , measles , mumps , rubella , oral polio , Bacillus CalmetteGuérin ( BCG ) , yellow fever , varicella TY21a typhoid vaccine ; 14 . Patients history another primary malignancy unless patient disease free &gt; /= 3 year ; 15 . Patients history noncompliance medical regimen consider potentially unreliable able complete entire study ; 16 . Patients currently part participate clinical investigation investigational drug within 1 month prior dose ( except ALK inhibitor ) ; 17 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . 18 . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , unless use highly effective method contraception dose 3 month last dose study treatment . Highly effective contraception method include : . Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . b . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Exclusion criterion continue # 19 . 19 . Exclusion criterion # 18 continue : c. Male sterilization ( least 6 month prior screen ) appropriate postvasectomy documentation absence sperm ejaculate . For female subject study vasectomized male partner sole partner subject . d. Combination two follow ( i+ii i+iii ii+iii ) : . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . ii . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . iii . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository . Exclusion criterion continue # 20 . 20 . Exclusion criterion # 18 continue # 19 : In case use oral contraception , woman stable pill minimum 3 month take study treatment . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g. , age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week prior screen . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 21 . Sexually active male unless use condom intercourse take drug 3 month last dose study treatment . Male patient 3 month father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid . Also male patient whose sexual partner ( ) WOCBP willing use adequate contraception study 8 week end enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Non small cell lung</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Metastatic solid tumor</keyword>
	<keyword>Anaplastic lymphoma kinase</keyword>
	<keyword>ALK</keyword>
	<keyword>Ceritinib</keyword>
	<keyword>LDK378</keyword>
	<keyword>Zykadia</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>Zortress</keyword>
	<keyword>RAD001</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>PK</keyword>
	<keyword>Biomarker test</keyword>
</DOC>